BioSpace News Archive

Azenta, Inc. announced that Company management will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022, which includes a presentation beginning at 10:30 a.m. EST.

ICU Medical, Inc. today announced the time of its fourth quarter 2021 earnings release and conference call. The Company will release its fourth quarter 2021 results on Thursday, February 24th , 2022 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET.

Company’s solutions and partnerships play key role in helping clinical trial investigator sites and participants take part in oncology studies.

Agilent Technologies Inc. (NYSE: A) highlights innovative laboratory automation solutions at the SLAS2022 International Conference and Exhibition held February 5 through February 9, 2022, at the Boston Convention and Exhibition Center in Boston, Massachusetts.

Surmodics, Inc. will hold its Annual Meeting of Shareholders on Thursday, February 10, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting.

Today, Ambu announces the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is Ambu’s first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology.

Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”).

If you purchased OWC Pharmaceutical Research Corp. stock between November 2016 and September 2017, you may be eligible for distribution from the Jeffrey Friedland Fair Fund

Altamira Therapeutics Ltd. today announced that it has established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio.

CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus five (AAV5)-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder.